Interleukin-2 in the Complex Treatment of Surgical Patients

Cover Page

Cite item

Full Text

Abstract

Immunotherapy for surgical diseases remains one of the urgent scientific and clinical issues. Immunodeficiency is manifested in patients with purulent wounds, pancreatic necrosis, osteomyelitis, oncological diseases, echinococcosis, gastroduodenal ulcers and other pathology. Drugs inducing interleukin-2 synthesis have shown high efficacy for the correction of immunodeficiency status. Clinical effects of rIL-2 are due to its ability to activate clonal proliferation of T- and B-lymphocytes, to enhance the effector potential of cytotoxic T-lymphocytes (CTL cells) and natural killer cells (NK cells), functional activity of mononuclear phagocytes and antigen-presenting cells, synthesis of specific immunoglobulins of most isotypes by plasma cells and to reduce apoptosis of mononuclears. This cytokine is a key link determining the development of cellular and humoral immunity. Interleukin-2 provides antitumor, antiviral, antibacterial and antifungal protection, being able to stimulate the processes of tissue regeneration and repair. The high clinical activity of the drug was revealed in the treatment of endotoxicosis, immunological insufficiency, inflammatory diseases in patients with surgical, oncological, traumatological, combustiological, resuscitation profiles, involving abdominal organs, pelvis and retroperitoneal space. It is rational to use recombinant interleukin-2 in case of previous inefficient conventional treatment and the process chronization. The drug has a number of positive aspects: rapid effect; reduced terms of treatment, frequency of infectious complications and sepsis; reduced mortality rate. The negative side of its administration is its high cost. Thus, immunosuppressive conditions are manifested in multiple surgical diseases. High clinical efficacy of recombinant interleukin 2, absence of complications, adverse reactions and undesirable effects, and favourable tolerability of the drug allow recommending it for wider use in surgical practice.

About the authors

Alexander Alekseevich Andreev


N.N. Burdenko Voronezh State Medical University

Email: mail@vestnik-surgery.com

M.D., Professor of the Department of General and Outpatient Surgery of N.N. Burdenko Voronezh State Medical University

Russian Federation, Voronezh, Russian Federation

Vitalii Donchenko

N.N. Burdenko Voronezh State Medical University

Email: sugery@mail.ru

Ph.D., associate Professor of the Department of General and Outpatient Surgery of N.N. Burdenko Voronezh State Medical University

Russian Federation, Voronezh, Russian Federation

Alexander Anatolievich Gluhov

N.N. Burdenko Voronezh State Medical University

Email: glukhov-vrn@yandex.ru

M.D., head of the Department of General and Outpatient Surgery, N.N. Burdenko Voronezh State Medical University

Russian Federation, Voronezh, Russian Federation

Vladislav Valeryevich Novomlinsky

CHUZ Clinical Hospital "Russian Railways-Medicine" of Voronezh
N.N. Burdenko Voronezh State Medical University

Email: sugery@mail.ru

Deputy Chief Physician for Surgical Care of the CHUZ Clinical Hospital "Russian Railways-Medicine" of Voronezh, assistant of the Department of General and Outpatient Surgery of the N.N. Burdenko Voronezh State Medical University

Russian Federation, Voronezh, Russia

Anton Petrovich Ostroushko

N.N. Burdenko Voronezh State Medical University

Email: anton@vrngmu.ru

Ph.D., associate Professor of the Department of General and Outpatient Surgery of N.N. Burdenko Voronezh State Medical University

Russian Federation, Voronezh, Russian Federation

Anastasia Yurievna Laptiyova

N.N. Burdenko Voronezh State Medical University

Author for correspondence.
Email: laptievaa@mail.ru

graduate student at the Department of General and Outpatient Surgery N.N. Burdenko Voronezh State Medical University

Russian Federation, Voronezh, Russian Federation

References

  1. Zinkovich SA, Zlatnik EYu, Zakora GI, Anistratov PA. Intraoperative use of ronkoleikin in the treatment of patients with resectable non-small cell lung cancer. Akademicheskii zhurnal Zapadnoi Sibiri.2012; 1: 23. (in Russ.)
  2. Styazhkina SN, Sharafieva RV, Serazieva AI, Mashenina PYu. Application and effectiveness of splenopid and roncoleukin in the treatment of purulent-inflammatory and immunodeficiency diseases. Sovremennye tendentsii razvitiya nauki i tekhnologii. 2016; 1-3:113-116. (in Russ.)
  3. Styazhkina SN, Akimov AA, Ledneva AV, Matusevich AE, Bashkirov AA, Gimranova AYa, Mustafina RH. The use of ronkoleikin in pancreatic necrosis in women in the postpartum period. Sovremennye tendentsii razvitiya nauki i tekhnologii. 2016; 12-2: 87-90. (in Russ.)
  4. Styazhkina SN, Akimov AA, Asoskova AA, Plotnikova EM. Cytokinotherapy of roncoleukin in the treatment of pancreatic necrosis. Sovremennye tendentsii razvitiya nauki i tekhnologii. 2016; 12-2: 95-98. (in Russ.)
  5. Berezhko VK, Sasikova MR, Haidarova AA. The study of the immunotherapeutic effect of the roncoleukin immunomodulator in secondary alveolar echinococcosis. Teoriya i praktika bor'by s parazitarnymi boleznyami. 2016; 17: 58-61. (in Russ.)
  6. Kulemin ME, Chernova AA, Styazhkina SN, Bairamkulov ED, Fedorov V, Kiryanov NA, Emelyanov AM. Local treatment of purulent-inflammatory diseases of soft tissues preparations "Roncoleukin" and "dimexide". Academy. 2019; 1 (40): 75-76. (in Russ.)
  7. Mammadov AM, Eyvazova KA, Tairova ZA, Mammadov RA. The role of recombinant interleukin-2 roncoleukin in the complex treatment of gastroduodenal ulcers.Vestnik khirurgii Kazakhstana. 2011; 1 (25): 26-28. (in Russ.)
  8. Zhankin BA, Alkhodzhaev SS, Kilybaev AK, Dzhaksybaev MN, Nurlybekov DK. Ronkoleikin in the complex treatment of chronic osteomyelitis. Vestnik Kazakhskogo natsional'nogo meditsinskogo universiteta. 2017; 3-2: 225-227. (in Russ.)
  9. Styazhkina SN, Akimov AA, Asoskova AA, Plotnikova EM. The effectiveness of roncoleukin in the treatment of pancreatic necrosis by the example of a clinical case. Nauchnyi zhurnal. 2016; 12 (13): 86-87. (in Russ.)
  10. Styazhkina SN, Krasnoperova OV, Kuznetsov SV, Khazieva LD, Gorshkov MS, Akimov AA. The use of ronkoleikin in the complex treatment of patients with acute destructive pancreatitis. Mezhdunarodnyi zhurnal prikladnykh i fundamental'nykh issledovanii. 2017; 6-1: 119-121. (in Russ.)
  11. Polyansky MB, Nazarenko PM, Ishunina TA, Nazarenko DP, Tarasov ON. The use of roncoleukin for the correction of secondary immunodifecitis in elderly and senile patients with acute cholecystitis. Rossiiskii immunologicheskii zhurnal. 2017; 11(20): 3: 470-471. (in Russ.)
  12. Styazhkina SN, Sitnikov VA, Ledneva AV, Khabibullina GV. Clinical efficacy of treatment of patients with peritonitis using the drug "ronkoleikin". Sovremennye tendentsii razvitiya nauki i tekhnologii. 2016; 4-2: 92-99. (in Russ.)
  13. Galimova AR, Bannikova VA, Prikhodko AO, Prikhodko NN, Styazhkina SN. The effectiveness of ronkoleikin in the complex treatment of purulent-inflammatory and immunodeficiency diseases. Interaktivnaya nauka. 2016; 3: 42-45. (in Russ.)
  14. Shamsiev AM, Grishaev VV. Ronkoleikin in the complex treatment of metaepiphyseal osteomyelitis in young children. Tsitokiny i vospalenie. 2010; 9: 4: 47-50. (in Russ.)
  15. Avagimyan SV, Janet DA, MT. Didigov. Roncoleukin in the correction of immune deficiency in patients with acute destructive pancreatitis. Kubanskii nauchnyi meditsinskii vestnik. 2010; 9 (123): 11–13. (in Russ.)
  16. Кaripidi GK, Babenko ES. The use of intraoperative Roncoleukin in the surgical treatment of perforated duodenal ulcers. Kubanskii nauchnyi meditsinskii vestnik. 2010; 9 (123): 98-101. (in Russ.)
  17. Tusupkaliev AB, Baubekov ZhT. Immunological characteristics of the effectiveness of topical application of roncoleukin in children with peritonitis. Uspekhi sovremennogo estestvoznaniya. 2015; 9: 92-94. (in Russ.)
  18. Suprun EV. The influence of roncoleukin on the activity of the nitric oxide system in the brain of rats with experimental hemorrhagic stroke. Ukrainskii zhurnal ekstremal'noi meditsiny imeni G.A.Mozhaeva. 2010; 11: 4: 117-121. (in Russ.)
  19. Alekhnovich AV, Ivanov VB, Livanov AS. Yeast recombinant interleukin-2 (roncoleukin) in the complex therapy of chemical trauma. Biopreparaty. Profilaktika, diagnostika, lechenie. 2011; 2 (42): 26-29. (in Russ.)
  20. Sachivko NV, Zhavrid EA, Baranov EV, Kolenik OA. Interleukin-2 (roncoleukin) in the first line of chemotherapy of b-cell non-Hodgkin's lymphomas. Voprosy onkologii. 2013; 59: 2: 52-58.(in Russ.)
  21. Booth NA, Suprun EV, Gromov LA, Piminov AF. The influence of roncoleukin on the effects of the nitric oxide system in the brain of rats with experimental hemorrhagic stroke. Patologiya. 2012; 3: 123. (in Russ.)
  22. Zubritsky VF, PG Bruce, EM. Fominykh, Grassroots AV, Kuleznev RA, Islamov RN, Samoilov OA. The use of yeast recombinant interleukin-2 (Roncoleukin) in an emergency to prevent postoperative infectious complications in patients with diabetes mellitus type 2. Biopreparaty. Profilaktika, diagnostika, lechenie. 2011; 3 (43): 27-31. (in Russ.)
  23. Suprun EV. Effects of oxidative modification of proteins and the formation of neurological dysfunctions in experimental ischemic stroke on the background of roncoleikin correction. Ukrainskii zhurnal ekstremal'noi meditsiny imeni G.A. Mozhaeva. 2011; 12: 3: 87-94. (in Russ.)
  24. Kosinets VA. The effect of interleukin-2 on the structural state of the small intestine in experimental widespread purulent peritonitis. Novosti khirurgii. 2014; 22: 6: 643-648. (in Russ.)
  25. Suprun EV, But NA, Tereshchenko SV. Dynamics of neurological disorders in experimental hemorrhagic stroke on the background of correction with interleukin-2 (roncoleukin). Kazanskii meditsinskii zhurnal. 2014; 95: 6: 801-806. (in Russ.)
  26. Avakimyan SV, Karipidi GK, Avakimyan VA, Didigov MT. Our experience in the treatment of acute destructive pancreatitis with roncoleikin. Kubanskii nauchnyi meditsinskii vestnik. 2013; 3 (138): 21-24. (in Russ.)
  27. Molchanov OE. Modern prognostic systems in assessing the effectiveness of systemic chemoimmunotherapy of renal cell carcinoma using recombinant interleukin-2. Vestnik Sankt-Peterburgskogo universiteta. Meditsina. 2013; 2: 141-147. (in Russ.)
  28. Kosinets VA. Immunocorrecting therapy in the complex treatment of widespread purulent peritonitis. Mediko-biologicheskie i sotsial'no-psikhologicheskie problemy bezopasnosti v chrezvychainykh situatsiyakh. 2012; 4: 46-49. (in Russ.)
  29. Styazhkina SN, Akhmedkhanov GR, Heydarova PA, Yuldashev ASh. Treatment of patients with diabetic foot syndrome "ronkoleikin".Nauka i obrazovanie segodnya. 2017; 5 (16): 77-79. (in Russ.)
  30. Bubnova NA, Egorova VN. Recombinant interleukin-2 in the treatment of diabetic foot syndrome. Glavnyi vrach Yuga Rossii. 2021; 5 (80): 66-67. (in Russ.)
  31. Kiselevsky MV, Chikileva IO, Zharkova OV, Ziganshina NV, Korolenkova LI, Sitdikova SM. Prospects of combined therapy of oncological patients with interleukin-2 and inhibitors of control immune points. Voprosy onkologii. 2020; 66: 1: 23-28. (in Russ.)
  32. Agliullina DR, Styazhkina SN. Our experience of using roncoleukin in the treatment of acute destructive pancreatitis. Modern Science. 2021; 4-4: 18-21. (in Russ.)
  33. Hasanov IA, Kosaev DV. Combined use of intravenous laser therapy, intraosseous laser irradiation and roncoleukin in indirect revascularization in patients with distal arterial lesion with critical lower limb ischemia. Lazernaya meditsina. 2019; 23: S3: 16. (in Russ.)
  34. Hajiyev DN, Tagiyev EG, Gadzhiev ND. Comparative assessment of interleukin-6 in liver tissue, ductal bile, blood serum and urine in patients with obstructive jaundice of benign etiology. Vestnik eksperimental'noi i klinicheskoi khirurgii. 2016; 9: 1:. 33-38.(in Russ.)
  35. Mikhailov AYu, Styazhkina SN, Fahrutdinova AR, Osipova IA, Hayrapetyan HT. Pathogenesis and treatment of diabetic foot syndrome. Modern Science. 202; 12-2: 84-86. (in Russ.)
  36. Mikhailov AYu, Styazhkina SN, Kamasheva YP, Ishkildin OA, Volkova EA. For purulent peritonitis on the background of decompensation of diabetes mellitus type 2. Modern Science. 2021; 12-2: 89-91. (in Russ.)
  37. Nikolaeva AR, Styazhkina SN, Emelyanova AM. Osobennosti techeniya ranevogo protsessa pri primenenii "ronkoleikina" i mazi "levomekolya" pri lechenii gnoinykh ran. V sbornike: Sbornik izbrannykh statei po materialam nauchnykh konferentsii GNII "Natsrazvitie". Sankt-Peterburg. 2021; 55-58. (in Russ.)

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Andreev A.A., Donchenko V., Gluhov A.A., Novomlinsky V.V., Ostroushko A.P., Laptiyova A.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies